How Much Does Jatenzo Cost in Nebraska in 2026?

Nebraska Retail Pricing for Jatenzo

The average cash price for a 30-day supply of Jatenzo at Nebraska retail pharmacies sits at approximately $900 in 2026. That figure matches the manufacturer list price set by Tolmar, the company that markets Jatenzo. Prices vary only slightly between chain pharmacies in Omaha, Lincoln, and smaller cities across the state.

Jatenzo was the first oral testosterone replacement therapy approved by the FDA in March 2019 for adult males with hypogonadism caused by specific medical conditions. The approval was based on data from a key trial by Swerdloff et al. (2020) that enrolled 166 hypogonadal men across multiple U.S. sites. In that study, 87% of men on the 237 mg twice-daily dose achieved a mean serum testosterone concentration within the normal range (300 to 1 to 100 ng/dL) at day 90. The mean Cavg was 489 ng/dL.

Unlike injectable testosterone cypionate, which costs between $30 and $80 per month for a generic vial, Jatenzo has no generic equivalent. That single-source status explains the $900 price point. Patients paying cash should compare prices across pharmacies using discount platforms, since posted prices do not always reflect negotiated rates.

Does Nebraska Medicaid Cover Jatenzo?

No. Nebraska Medicaid does not cover Jatenzo as of 2026. The state's Medicaid formulary excludes brand-name oral testosterone undecanoate, and no exception pathway has been published for this drug class.

Nebraska expanded Medicaid eligibility under the ACA in 2020, adding roughly 90,000 adults. But expansion did not change the formulary decision for Jatenzo. The Nebraska Department of Health and Human Services maintains a preferred drug list that favors lower-cost injectable and topical testosterone formulations. Generic testosterone cypionate (200 mg/mL) and generic topical testosterone gel 1% both appear on the preferred list. Patients enrolled in Heritage Health (the state's managed Medicaid program through Aetna, Molina, or UnitedHealthcare Community Plan) face the same restriction. A prescriber could attempt a prior authorization, but approvals for Jatenzo under Nebraska Medicaid remain uncommon. Documented intolerance or contraindication to injectable and topical options would be the strongest clinical basis for such a request.

For men on Nebraska Medicaid who need testosterone replacement, injectable testosterone cypionate (typically 100 to 200 mg every one to two weeks) remains the most accessible covered option. The Endocrine Society's 2018 clinical practice guideline lists both injectable and oral formulations as appropriate for treating male hypogonadism, but payer decisions in Nebraska heavily favor injectables on cost grounds.

Commercial Insurance Coverage in Nebraska

Several major commercial insurers in Nebraska will cover Jatenzo, though nearly all require prior authorization and step therapy. BlueCross BlueShield of Nebraska, UnitedHealthcare, and Aetna each list Jatenzo on their formularies at a non-preferred brand tier (typically Tier 3 or Tier 4).

What "step therapy" means in practice: the insurer requires documentation that the patient tried and failed (or cannot use) a lower-cost testosterone formulation before approving Jatenzo. Common step-therapy requirements include a 60- to 90-day trial of injectable testosterone cypionate or a topical gel. A confirmed diagnosis of hypogonadism with two separate morning total testosterone levels below 300 ng/dL is a baseline requirement per Endocrine Society guidelines.

Even after approval, the patient copay on a Tier 3 or Tier 4 brand drug can range from $75 to $250 per month depending on the specific plan. That is where manufacturer savings programs become valuable.

Employer-sponsored plans in Nebraska (which cover approximately 53% of the state's non-elderly population, according to Kaiser Family Foundation estimates) vary widely. Some self-insured employer plans exclude testosterone replacement therapy entirely, while others cover Jatenzo with a specialty-pharmacy copay. Patients should request a pharmacy benefit check before assuming coverage.

How the Tolmar Savings Card Works in Nebraska

Tolmar offers a copay savings card for Jatenzo that can reduce out-of-pocket costs to as low as $0 per month for eligible patients with commercial insurance. The card covers up to a specified annual maximum (historically $6,000 to $9,000 per year, though terms change annually).

Eligibility rules are standard for manufacturer copay cards. The patient must have commercial insurance that covers Jatenzo. Patients on government-funded insurance (Medicaid, Medicare, Tricare, VA) are not eligible. Nebraska residents with no insurance are also excluded from the copay card program, though Tolmar operates a separate patient assistance program for uninsured patients who meet income criteria.

To activate the card, patients register through Tolmar's Jatenzo website or call the support line. The card functions as a secondary payer at the pharmacy counter. When the pharmacist processes the prescription, the commercial insurance adjudicates first, and the savings card covers the remaining copay up to the card's limit.

One practical note: not all Nebraska pharmacies accept copay cards seamlessly on the first fill. If the pharmacy's system rejects the card, the pharmacist may need to manually enter the BIN and PCN numbers. Patients should bring the physical or digital card to their first fill rather than assuming the pharmacy has the information on file.

Compounded Oral Testosterone Undecanoate in Nebraska

Compounded oral testosterone undecanoate is available in Nebraska through licensed 503A compounding pharmacies. This is a legal option under federal and state law, provided the compounding pharmacy holds a valid Nebraska Board of Pharmacy license and prepares the medication pursuant to a patient-specific prescription.

The price difference is dramatic. Compounded oral testosterone undecanoate may cost significantly less than the $900 brand-name Jatenzo, though exact pricing depends on the compounding pharmacy, dosage, and capsule count. Some 503A pharmacies quote prices in the range of $50 to $200 per month for oral testosterone undecanoate capsules.

There are clinical considerations. Compounded formulations are not FDA-approved, meaning they have not undergone the same bioequivalence testing as Jatenzo. The FDA's guidance on compounding clarifies that 503A pharmacies may compound drugs that are commercially available if the prescriber determines a clinical need (such as a dose or formulation that differs from the commercial product). Nebraska does not have a state-level ban on compounding commercially available drugs through 503A pharmacies, unlike some states that have imposed additional restrictions.

The Swerdloff et al. trial that supported Jatenzo's approval used a self-emulsifying drug delivery system (SEDDS) designed to improve lymphatic absorption when taken with food. Compounded oral testosterone undecanoate capsules may use different excipients, which could affect absorption kinetics. Prescribers should monitor serum testosterone levels (drawn 3 to 5 hours post-dose) after switching between brand and compounded formulations to confirm adequate absorption.

Dr. Abraham Morgentaler, Associate Clinical Professor of Urology at Harvard Medical School, has stated: "Oral testosterone undecanoate represents a genuine advance in convenience for men with hypogonadism, but the absorption profile depends heavily on the formulation. Monitoring testosterone levels after any formulation change is standard practice."

Telehealth Prescribing of Jatenzo in Nebraska

Telehealth prescribing of Jatenzo is legal in Nebraska. The state permits licensed physicians and advanced practice providers to prescribe Schedule III controlled substances via telehealth, provided the prescriber holds an active Nebraska medical license (or practices under a valid interstate compact arrangement).

Nebraska adopted permanent telehealth prescribing rules following the pandemic-era flexibilities, aligning with the DEA's updated telemedicine prescribing rules. A prescriber must conduct an adequate medical evaluation, which for testosterone replacement means reviewing symptoms, confirming the diagnosis with laboratory results (two morning total testosterone levels below 300 ng/dL), and assessing cardiovascular risk factors.

Several national telehealth platforms now prescribe Jatenzo to Nebraska residents. Patients complete an intake, submit bloodwork, and receive a prescription sent to a Nebraska-licensed pharmacy. The telehealth visit itself typically costs $75 to $199 depending on the platform, separate from the medication cost. Some platforms include the Tolmar savings card enrollment as part of their onboarding.

One advantage of telehealth for Nebraska patients: access is more equitable across the state. Nebraska has 93 counties, many of which are rural. The state has approximately 6.8 endocrinologists per 100,000 residents in the Omaha-Lincoln metro area, but large portions of western Nebraska have no endocrinologist within 100 miles. Telehealth removes that geographic barrier.

How Jatenzo Compares to Other Testosterone Options on Cost

Jatenzo at $900 per month is the most expensive standard testosterone replacement option available in Nebraska. Here is how the common alternatives compare on a monthly cash-price basis at Nebraska pharmacies:

Generic testosterone cypionate (200 mg/mL, 10 mL vial): $30 to $80 per month. Requires intramuscular injection every 1 to 2 weeks. Covered by Nebraska Medicaid.

Generic testosterone gel 1% (pump or packet): $50 to $150 per month. Applied daily to skin. Risk of transference to household contacts. Covered by Nebraska Medicaid.

Testosterone patch (Androderm generic): $150 to $300 per month. Applied nightly. Skin irritation is common. Variable Medicaid coverage.

Testosterone pellets (Testopel): $500 to $900 per insertion, repeated every 3 to 6 months. Requires a minor in-office procedure. Rarely covered by Medicaid.

Jatenzo's clinical value proposition is convenience: no injections, no skin transference risk, no patches. The Swerdloff et al. study demonstrated that 87% of subjects achieved eugonadal testosterone levels, with a mean Cavg of 489 ng/dL. Adverse events included increased blood pressure in some subjects; the FDA label carries a boxed warning about blood pressure elevation and requires monitoring. A follow-up cardiovascular outcomes analysis showed that systolic blood pressure increased by a mean of 3 to 5 mmHg in the treatment group, which led the FDA to recommend blood pressure monitoring at baseline, after 1 month, and periodically thereafter.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, evaluated cardiovascular safety of testosterone replacement (using topical gel, not Jatenzo specifically) and found that testosterone replacement did not increase the incidence of major adverse cardiovascular events compared to placebo in men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease. The hazard ratio for the primary composite endpoint was 0.96 (95% CI, 0.78 to 1.17). This trial addressed a long-standing safety concern about testosterone therapy.

Strategies to Reduce Jatenzo Cost in Nebraska

For Nebraska patients who want Jatenzo specifically, a few cost-reduction strategies exist. First, confirm insurance coverage and complete any required step therapy promptly. Have your prescriber submit a prior authorization with documentation of failed alternatives.

Second, enroll in the Tolmar savings card immediately. Even a $150 copay drops to $0 with the card for most commercially insured patients.

Third, ask your prescriber about dose optimization. Jatenzo is dosed at 158 mg, 198 mg, or 237 mg twice daily, titrated based on serum testosterone levels drawn 3 to 5 hours post-dose. Some patients achieve target levels at the 158 mg dose, and capsule count per month may vary by dose, potentially affecting price at some pharmacies.

Fourth, consider a licensed 503A compounding pharmacy if brand-name cost is prohibitive and your prescriber supports the switch. Verify that the pharmacy is licensed by the Nebraska Board of Pharmacy and request third-party potency testing results.

Dr. Shalender Bhasin, Professor of Medicine at Harvard Medical School and principal investigator of the TRAVERSE trial, has noted: "The choice of testosterone formulation should be individualized based on patient preference, cost, and clinical response. No single formulation is superior in efficacy; the differences are in route, convenience, and side-effect profile."

Fifth, patients with incomes below 400% of the federal poverty level should contact Tolmar's patient assistance program directly. Income thresholds and documentation requirements change annually, but the program has historically provided free medication to qualifying uninsured patients.

The current federal poverty level for a single individual in 2026 is $15,650, making the 400% threshold $62 to 600 in annual income. Nebraska's median household income is approximately $71,000, which means a significant number of single adults and smaller households may qualify.